Express Scripts knocks many newer brands off formulary

Share this article:

Express Scripts, the big PBM, issued its new formulary for 2014, and a list accompanying the formulary shows many recently approved brands won't be covered, reports FiercePharma. Among those being excluded from reimbursement: Pfizer RA drug Xeljanz, Johnson & Johnson psoriasis treatment Stelara, and  GlaxoSmithKline respiratory drug Breo Ellipta. Alternatives are listed beside each.

It's the first time the PBM's preferred formulary designates certain drugs as “not covered,” an Express Scripts spokesman told FiercePharma, adding "Drug choices in some classes are larger than ever, with many products costing more with no additional health benefit."

The co-pay card, a marketing tactic often used by pharma to provide patient assistance for branded drugs, played into Express Scripts's decision, FiercePharma points out.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients